Rai Vikrant, Radwan Mohamed M, Nooti Sunil, Thankam Finosh G, Singh Harbinder, Agrawal Devendra K
Department of Translational Research, Western University of Health Sciences, Pomona, CA 91766, USA.
Cardiol Cardiovasc Med. 2022;6(5):432-450. doi: 10.26502/fccm.92920280. Epub 2022 Aug 26.
Arteriovenous fistula (AVF) is the preferred vascular access in hemodialysis patients; however, it is afflicted with a high failure rate. Chronic inflammation, excessive neointimal hyperplasia (NIH), vessel stenosis, early thrombosis, and failure of outward remodeling are the major causes of AVF maturation failure. Inflammatory mediator toll-like receptor (TLR)-4 plays a critical role in NIH, arterial thrombosis, and stenosis. We investigated the effect of TLR-4 inhibition on early thrombosis. Yucatan miniswine were used to create AVF involving femoral artery and femoral vein and treated with TLR-4 inhibitor TAK-242 with ethanol as the vehicle. The vessels were assessed after 12 weeks using histomorphometry, immunostaining, ultrasound, angiography, and optical coherence tomography. Inhibition of TLR-4 attenuated inflammation and early thrombosis in 50% of animals, and blood flow was present through AVF in 25% of animals. Thus, targeting TLR-4 to attenuate inflammation and early thrombosis might be a therapeutic approach to keep AVF patent and maintain blood flow through the outflow vein.
动静脉内瘘(AVF)是血液透析患者首选的血管通路;然而,其失败率很高。慢性炎症、过度的内膜增生(NIH)、血管狭窄、早期血栓形成以及向外重塑失败是AVF成熟失败的主要原因。炎症介质Toll样受体(TLR)-4在NIH、动脉血栓形成和狭窄中起关键作用。我们研究了抑制TLR-4对早期血栓形成的影响。使用尤卡坦小型猪建立涉及股动脉和股静脉的AVF,并以乙醇为载体用TLR-4抑制剂TAK-242进行治疗。12周后,使用组织形态计量学、免疫染色、超声、血管造影和光学相干断层扫描对血管进行评估。抑制TLR-4可减轻50%动物的炎症和早期血栓形成,25%的动物通过AVF有血流。因此,靶向TLR-4以减轻炎症和早期血栓形成可能是一种使AVF保持通畅并维持流出静脉血流的治疗方法。